Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities:
Net loss	$ (10,060,257)	$ (1,528,056)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation	2,797,807	76,882
Amortization of operating lease right-of-use asset	19,746
Depreciation	49,808
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(76,925)	(25,918)
Accounts payable	1,933,949	(146,692)
Accrued expenses	(1,810,087)	217,782
Net cash used in operating activities	(7,145,959)	(1,406,002)
Cash flows from investing activities:
Cash and restricted cash acquired in connection with the reverse merger with ArTara Therapeutics, Inc.	3,718,742
Purchase of property and equipment	(247,001)	(27,113)
Net cash provided by/(used in) investing activities	3,471,741	(27,113)
Cash flows from financing activities:
Proceeds from - ArTara Private Placement, net of offering costs	1,867,580
Proceeds from - Proteon Private Placement, net of offering costs	12,413,337
Proceeds from - Series 1 Convertible Preferred Stock, net of offering costs	25,318,706
Repayments under short-term debt	(370,793)
Net cash provided by financing activities	39,228,830
Net increase/(decrease) in cash and cash equivalents and restricted cash	35,554,612	(1,433,115)
Cash and cash equivalents and restricted cash - beginning of year	564,124	5,549,952
Cash and cash equivalents and restricted cash - end of year	36,118,736	4,116,837
Cash paid for:
Interest	7,529
Income Taxes
Non-cash investing and financing activities:
Deferred offering costs recognized that were previously recorded in accrued expenses	121,712
Purchase of insurance agreement with notes payable	1,668,570
Common stock issued in connection with the reverse merger with ArTara Therapeutics, Inc.	$ 34,532,627